Market revenue in 2021 | USD 6.9 billion |
Market revenue in 2030 | USD 11.1 billion |
Growth rate | 5.4% (CAGR from 2021 to 2030) |
Largest segment | Anti-hypertensive |
Fastest growing segment | Hormones |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD billion |
Market segmentation | Alkylating Agents, Antimetabolites, Hormones, Anti-hypertensive, Lipid Lowering drugs, Anti-depressants, Anti-psychotics, Anti-epileptics |
Key market players worldwide | Teva Pharmaceutical Industries Ltd, Lupin, Sanofi SA, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, GlaxoSmithKline, Pfizer Inc, Apotex Inc., Viatris Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to branded generics market will help companies and investors design strategic landscapes.
Anti-hypertensive was the largest segment with a revenue share of 15.94% in 2021. Horizon Databook has segmented the Brazil branded generics market based on alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptics covering the revenue growth of each sub-segment from 2018 to 2030.
The Brazilian branded generics market is anticipated to witness positive growth over the forecast period owing to factors such as increasing government initiatives and growing target patient population. According to a report, the Brazilian government spent around USD 8.61 billion in the hospital and outpatient care sector in 2020.
Generics represent approximately 28% of Brazil’s pharmaceuticals sales. The article further stated that physicians associated with National Health System are mandated to prescribe unbranded generic name, whereas private practitioners are not bound by any such law and can prescribe branded drugs in the country.
The universal health system of Brazil, also known as Sistema Unico de Saude, which intends to provide universal and free healthcare to the public, is expected to drive the adoption of generic drugs in the Brazilian market.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil branded generics market , including forecasts for subscribers. This country databook contains high-level insights into Brazil branded generics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account